What are the recommended malaria prophylaxis options for children traveling to areas with chloroquine-resistant malaria?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Malaria Prophylaxis Options for Children in Chloroquine-Resistant Areas

For children traveling to areas with chloroquine-resistant malaria, atovaquone-proguanil is the recommended first-line prophylactic agent due to its excellent efficacy and safety profile, while mefloquine is an appropriate alternative for children weighing more than 15 kg when atovaquone-proguanil cannot be used. 1, 2

First-Line Options

  • Atovaquone-proguanil (Malarone) is highly effective against drug-resistant strains of P. falciparum with 95-100% prophylactic efficacy 1
    • Dosage based on body weight for children ≥11 kg 1, 2
    • Only needs to be continued for 7 days after leaving the malaria-endemic area (unlike most other options which require 4 weeks) 1
    • Well-tolerated with fewer gastrointestinal adverse events compared to chloroquine-proguanil 2
    • Cannot be used in children weighing less than 11 kg 3

Alternative Options

  • Mefloquine is effective for prophylaxis in chloroquine-resistant areas 4

    • Contraindicated in children weighing less than 15 kg 5
    • Weekly dosing (5 mg/kg) may improve compliance compared to daily regimens 6
    • Should be avoided in children with history of seizures, psychiatric disorders, or taking medications that may prolong cardiac conduction 5
    • Neuropsychiatric side effects (including nightmares, anxiety, sleep disturbances) occur in some children, typically with the first three doses 5
    • Consider disguising the bitter taste to increase adherence in children 3
  • Doxycycline can be used as an alternative regimen 5

    • Contraindicated in children less than 8 years of age 5
    • Daily dosing required during travel and for 4 weeks after leaving the malarious area 5
    • Side effects include photosensitivity (minimize by avoiding sun exposure, using UVA-blocking sunscreens, and taking the drug in the evening) 5

Special Considerations

  • For children <8 years who cannot take mefloquine or atovaquone-proguanil: Options are limited, and travel to high-risk areas should be reconsidered 5

  • Medication administration tips:

    • Pediatric doses should be calculated carefully according to body weight 5
    • For chloroquine (when used): Pharmacists can prepare capsules with calculated pediatric doses; alternatively, mixing the powder in food or drink may facilitate administration 5
    • Store all antimalarial medications in child-proof containers out of children's reach as overdose can be fatal 5
  • Compliance is essential: Most malaria cases in travelers occur in those who do not fully comply with prophylaxis regimens 5

Prevention Beyond Medication

  • Apply insect repellents containing diethyltoluamide to exposed skin (follow manufacturer's recommendations for children) 5
  • Use bed nets treated with permethrin, especially for young children 5
  • Dress children in long-sleeved clothing and long trousers if outdoors after sunset 5
  • Start prophylaxis 1-2 weeks before travel (except doxycycline which can begin 1-2 days before) 5

Monitoring and Follow-up

  • Parents should be educated about malaria symptoms and the importance of seeking immediate medical attention if fever develops during or after travel 3
  • Even with appropriate prophylaxis, breakthrough infections can occur; malaria should always be suspected if a child becomes ill after travel to an endemic area 3

References

Research

Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004

Research

[Malaria and children who travel - prophylaxis and therapy].

Therapeutische Umschau. Revue therapeutique, 2013

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Malaria chemoprophylaxis in traveling children].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.